Nebivolol Teva (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors, which slows heart rate and reduces contractility. It also stimulates nitric oxide release from the endothelium, causing blood‑vessel relaxation and decreasing peripheral resistance, together lowering blood pressure.

The exact dose of Nebivolol Teva is determined by the prescribing clinician based on the patient’s condition, response, and any comorbidities. Dosage adjustments are made according to clinical guidelines and individual tolerance.

The safety of nebivolol in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a highly selective β1‑blocker that also enhances nitric oxide‑mediated vasodilation, which can provide better blood‑pressure control with fewer metabolic side effects compared with non‑selective beta‑blockers. Its dual action may be advantageous in patients who need both heart‑rate reduction and improved endothelial function.

Nebivolol Teva tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Nebivolol Teva is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare provider.

Serious risks include marked bradycardia, severe hypotension, heart block, and bronchospasm in patients with reactive airway disease. Patients should be monitored for these events, especially when initiating therapy or adjusting doses.

Nebivolol is contraindicated in patients with severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, and in those with known hypersensitivity to nebivolol or any of its excipients. Caution is also advised for individuals with uncontrolled asthma or severe chronic obstructive pulmonary disease.